CDH1 (gene)

From Wikipedia, the free encyclopedia
  (Redirected from E-cadherin)
Jump to: navigation, search
Cadherin 1, type 1, E-cadherin (epithelial)
PBB Protein CDH1 image.jpg
PDB rendering based on 1i7w.
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols CDH1 ; Arc-1; CD324; CDHE; ECAD; LCAM; UVO
External IDs OMIM192090 MGI88354 HomoloGene20917 GeneCards: CDH1 Gene
RNA expression pattern
PBB GE CDH1 201131 s at tn.png
PBB GE CDH1 201130 s at tn.png
More reference expression data
Orthologs
Species Human Mouse
Entrez 999 12550
Ensembl ENSG00000039068 ENSMUSG00000000303
UniProt P12830 P09803
RefSeq (mRNA) NM_004360 NM_009864
RefSeq (protein) NP_004351 NP_033994
Location (UCSC) Chr 16:
68.77 – 68.87 Mb
Chr 8:
106.6 – 106.67 Mb
PubMed search [1] [2]

Cadherin-1 also known as CAM 120/80 or epithelial cadherin (E-cadherin) or uvomorulin is a protein that in humans is encoded by the CDH1 gene.[1] CDH1 has also been designated as CD324 (cluster of differentiation 324). It is a tumor suppressor gene.[2][3]

Function[edit]

Cadherin-1 is a classical member of the cadherin superfamily. The encoded protein is a calcium-dependent cell-cell adhesion glycoprotein composed of five extracellular cadherin repeats, a transmembrane region, and a highly conserved cytoplasmic tail. Mutations in this gene are correlated with gastric, breast, colorectal, thyroid, and ovarian cancers. Loss of function is thought to contribute to progression in cancer by increasing proliferation, invasion, and/or metastasis. The ectodomain of this protein mediates bacterial adhesion to mammalian cells, and the cytoplasmic domain is required for internalization. Identified transcript variants arise from mutation at consensus splice sites.[4]

E-cadherin (epithelial) is the most well-studied member of the cadherin family. It consists of 5 cadherin repeats (EC1 ~ EC5) in the extracellular domain, one transmembrane domain, and an intracellular domain that binds p120-catenin and beta-catenin. The intracellular domain contains a highly-phosphorylated region vital to beta-catenin binding and, therefore, to E-cadherin function.[citation needed] Beta-catenin can also bind to alpha-catenin. Alpha-catenin participates in regulation of actin-containing cytoskeletal filaments. In epithelial cells, E-cadherin-containing cell-to-cell junctions are often adjacent to actin-containing filaments of the cytoskeleton.

E-cadherin is first expressed in the 2-cell stage of mammalian development, and becomes phosphorylated by the 8-cell stage, where it causes compaction.[citation needed] In adult tissues, E-cadherin is expressed in epithelial tissues, where it is constantly regenerated with a 5-hour half-life on the cell surface.[citation needed] Cell-cell interactions mediated by E-cadherin are crucial to blastula formation in many animals.[5]

Clinical significance[edit]

Loss of E-cadherin function or expression has been implicated in cancer progression and metastasis.[6] E-cadherin downregulation decreases the strength of cellular adhesion within a tissue, resulting in an increase in cellular motility. This in turn may allow cancer cells to cross the basement membrane and invade surrounding tissues.[6] E-cadherin is also used by pathologists to diagnose different kinds of breast cancer. When compared with invasive ductal carcinoma, E-cadherin expression is markedly reduced or absent in the great majority of invasive lobular carcinomas when studied by immunohistochemistry.[7]

Interactions[edit]

CDH1 (gene) has been shown to interact with

Cadherin-1 and cancer[edit]

Cadherin-1 in metastasis[edit]

Transitions between epithelial and mesenchymal states play important roles in embryonic development and cancer metastasis. E-cadherin level changes in EMT (epithelial-mesenchymal transition) and MET (mesenchymal-epithelial transition). E-cadherin acts as an invasion suppressor and a classical tumor suppressor gene in pre-invasive lobular breast carcinoma.[48]

1. E-cadherin in EMT:

E-cadherin is a crucial type of cell-cell adhesion to hold the epithelial cells tight together. E-cadherin can sequester β-catenin on the cell membrane by the cytoplasmic tail of E-cadherin. Loss of E-cadherin expression results in releasing β-catenin into the cytoplasm. Liberated β-catenin molecules may migrate into the nucleus and trigger the expression of EMT-inducing transcription factors. Together with other mechanisms, such as constitutive RTK activation, E-cadherin loss can lead cancer cells to the mesenchymal state and undergo metastasis. E-cadherin is an important switch in EMT.[48]

2. E-cadherin in MET:

The mesenchymal state cancer cells migrate to new sites and may undergo METs in certain favorable microenvironment. For example, the cancer cells can recognize differentiated epithelial cell features in the new sites and upregulate E-cadherin expression. Those cancer cells can form cell-cell adhesions again and return to an epithelial state.[48]

Cancer examples[edit]

  • Inactivation of CDH1 (accompany with loss of the wild-type allele) in 56% of lobular breast carcinomas.[49][50]
  • Inactivation of CDH1 in 50% of diffuse gastric carcinomas.[51]
  • Complete loss of E-cadherin protein expression in 84% of lobular breast carcinomas.[52]

Genetic and epigenetic control of CDH1[edit]

Several proteins such as SNAI1/SNAIL,[53][54] ZFHX1B/SIP1,[55] SNAI2/SLUG,[56][57] TWIST1[58] and DeltaEF1[59] have been found to downregulate E-cadherin expression. When expression of those transcription factors is altered, transcriptional repressors of E-cadherin were overexpressed in tumor cells.[53][54][55][56][58][59] Another group of genes, such as AML1, p300 and HNF3,[60] can upregulate the expression of E-cadherin.[61]

In order to study the epigenetic regulation of E-cadherin, M Lombaerts et al. performed a genome wide expression study on 27 human mammary cell lines. Their results revealed two main clusters that have the fibroblastic or epithelial phenotype, respectively. In close examination, the clusters showing fibroblast phenotypes only have either partial or complete CDH1 promoter methylation, while the clusters with epithelial phenotypes have both wild-type cell lines and cell lines with mutant CDH1 status. The authors also found that EMT can happen in breast cancer cell lines with hypermethylation of CDH1 promoter, but in breast cancer cell lines with a CDH1 mutational inactivation EMT cannot happen. It contradicts the hypothesis that E-cadherin loss is the initial or primary cause for EMT. In conclusion, the results suggest that “E-cadherin transcriptional inactivation is an epi-phenomenon and part of an entire program, with much more severe effects than loss of E-cadherin expression alone”.[61]

Other studies also show that epigenetic regulation of E-cadherin expression occurs during metastasis. The methylation patterns of the E-cadherin 5’ CpG island are not stable. During metastatic progression of many cases of epithelial tumors, a transient loss of E-cadherin is seen and the heterogeneous loss of E-cadherin expression results from a heterogeneous pattern of promoter region methylation of E-cadherin.[62]

See also[edit]

References[edit]

  1. ^ Huntsman DG, Caldas C (Mar 1999). "Assignment1 of the E-cadherin gene (CDH1) to chromosome 16q22.1 by radiation hybrid mapping". Cytogenet Cell Genet 83 (1-2): 82–3. doi:10.1159/000015134. PMID 9925936. 
  2. ^ Semb H, Christofori G (December 1998). "The tumor-suppressor function of E-cadherin". Am. J. Hum. Genet. 63 (6): 1588–93. doi:10.1086/302173. PMC 1377629. PMID 9837810. 
  3. ^ Wong AS, Gumbiner BM (June 2003). "Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin". J. Cell Biol. 161 (6): 1191–203. doi:10.1083/jcb.200212033. PMC 2173007. PMID 12810698. 
  4. ^ "Entrez Gene: CDH1 cadherin 1, type 1, E-cadherin (epithelial)". 
  5. ^ Fleming TP, Papenbrock T, Fesenko I, Hausen P, Sheth B (August 2000). "Assembly of tight junctions during early vertebrate development". Semin. Cell Dev. Biol. 11 (4): 291–9. doi:10.1006/scdb.2000.0179. PMID 10966863. 
  6. ^ a b Weinberg, Robert (2006). The Biology of Cancer. Garland Science. pp. 864 pages. ISBN 9780815340782. 
  7. ^ Rosen, P. Rosen's Breast Pathology, 3rd ed, 2009, p. 704. Lippincott Williams & Wilkins.
  8. ^ Fujita Y, Krause G, Scheffner M, Zechner D, Leddy HE, Behrens J, Sommer T, Birchmeier W (2002). "Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex". Nature Cell Biology 4 (3): 222–231. doi:10.1038/ncb758. PMID 11836526.  edit
  9. ^ Vodermaier HC, Gieffers C, Maurer-Stroh S, Eisenhaber F, Peters JM (September 2003). "TPR subunits of the anaphase-promoting complex mediate binding to the activator protein CDH1". Curr. Biol. 13 (17): 1459–68. doi:10.1016/S0960-9822(03)00581-5. PMID 12956947. 
  10. ^ a b Kang JS, Feinleib JL, Knox S, Ketteringham MA, Krauss RS (April 2003). "Promyogenic members of the Ig and cadherin families associate to positively regulate differentiation". Proc. Natl. Acad. Sci. U.S.A. 100 (7): 3989–94. doi:10.1073/pnas.0736565100. PMC 153035. PMID 12634428. 
  11. ^ Klingelhöfer J, Troyanovsky RB, Laur OY, Troyanovsky S (August 2000). "Amino-terminal domain of classic cadherins determines the specificity of the adhesive interactions". J. Cell. Sci. 113 (16): 2829–36. PMID 10910767. 
  12. ^ Daniel JM, Reynolds AB (September 1995). "The tyrosine kinase substrate p120cas binds directly to E-cadherin but not to the adenomatous polyposis coli protein or alpha-catenin". Mol. Cell. Biol. 15 (9): 4819–24. PMC 230726. PMID 7651399. 
  13. ^ Ireton RC, Davis MA, van Hengel J, Mariner DJ, Barnes K, Thoreson MA, Anastasiadis PZ, Matrisian L, Bundy LM, Sealy L, Gilbert B, van Roy F, Reynolds AB (November 2002). "A novel role for p120 catenin in E-cadherin function". J. Cell Biol. 159 (3): 465–76. doi:10.1083/jcb.200205115. PMC 2173073. PMID 12427869. 
  14. ^ a b c d Kinch MS, Clark GJ, Der CJ, Burridge K (July 1995). "Tyrosine phosphorylation regulates the adhesions of ras-transformed breast epithelia". J. Cell Biol. 130 (2): 461–71. doi:10.1083/jcb.130.2.461. PMC 2199929. PMID 7542250. 
  15. ^ a b c d Hazan RB, Norton L (April 1998). "The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton". J. Biol. Chem. 273 (15): 9078–84. doi:10.1074/jbc.273.15.9078. PMID 9535896. 
  16. ^ Bonné S, Gilbert B, Hatzfeld M, Chen X, Green KJ, van Roy F (April 2003). "Defining desmosomal plakophilin-3 interactions". J. Cell Biol. 161 (2): 403–16. doi:10.1083/jcb.200303036. PMC 2172904. PMID 12707304. 
  17. ^ a b c Piedra J, Miravet S, Castaño J, Pálmer HG, Heisterkamp N, García de Herreros A, Duñach M (April 2003). "p120 Catenin-associated Fer and Fyn tyrosine kinases regulate beta-catenin Tyr-142 phosphorylation and beta-catenin-alpha-catenin Interaction". Mol. Cell. Biol. 23 (7): 2287–97. doi:10.1128/MCB.23.7.2287-2297.2003. PMC 150740. PMID 12640114. 
  18. ^ a b Shibamoto S, Hayakawa M, Takeuchi K, Hori T, Miyazawa K, Kitamura N, Johnson KR, Wheelock MJ, Matsuyoshi N, Takeichi M (March 1995). "Association of p120, a tyrosine kinase substrate, with E-cadherin/catenin complexes". J. Cell Biol. 128 (5): 949–57. doi:10.1083/jcb.128.5.949. PMC 2120395. PMID 7876318. 
  19. ^ Ohkubo T, Ozawa M (July 1999). "p120(ctn) binds to the membrane-proximal region of the E-cadherin cytoplasmic domain and is involved in modulation of adhesion activity". J. Biol. Chem. 274 (30): 21409–15. doi:10.1074/jbc.274.30.21409. PMID 10409703. 
  20. ^ Davies G, Jiang WG, Mason MD (April 2001). "HGF/SF modifies the interaction between its receptor c-Met, and the E-cadherin/catenin complex in prostate cancer cells". Int. J. Mol. Med. 7 (4): 385–8. doi:10.3892/ijmm.7.4.385. PMID 11254878. 
  21. ^ Kucerová D, Sloncová E, Tuhácková Z, Vojtechová M, Sovová V (December 2001). "Expression and interaction of different catenins in colorectal carcinoma cells". Int. J. Mol. Med. 8 (6): 695–8. doi:10.3892/ijmm.8.6.695. PMID 11712088. 
  22. ^ Oyama T, Kanai Y, Ochiai A, Akimoto S, Oda T, Yanagihara K, Nagafuchi A, Tsukita S, Shibamoto S, Ito F (December 1994). "A truncated beta-catenin disrupts the interaction between E-cadherin and alpha-catenin: a cause of loss of intercellular adhesiveness in human cancer cell lines". Cancer Res. 54 (23): 6282–7. PMID 7954478. 
  23. ^ a b Hazan RB, Kang L, Roe S, Borgen PI, Rimm DL (December 1997). "Vinculin is associated with the E-cadherin adhesion complex". J. Biol. Chem. 272 (51): 32448–53. doi:10.1074/jbc.272.51.32448. PMID 9405455. 
  24. ^ Jiang MC, Liao CF, Tai CC (June 2002). "CAS/CSE 1 stimulates E-cadhrin-dependent cell polarity in HT-29 human colon epithelial cells". Biochem. Biophys. Res. Commun. 294 (4): 900–5. doi:10.1016/S0006-291X(02)00551-X. PMID 12061792. 
  25. ^ Bonvini P, An WG, Rosolen A, Nguyen P, Trepel J, Garcia de Herreros A, Dunach M, Neckers LM (February 2001). "Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription". Cancer Res. 61 (4): 1671–7. PMID 11245482. 
  26. ^ Li Y, Bharti A, Chen D, Gong J, Kufe D (December 1998). "Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin". Mol. Cell. Biol. 18 (12): 7216–24. PMC 109303. PMID 9819408. 
  27. ^ Wendeler MW, Praus M, Jung R, Hecking M, Metzig C, Gessner R (April 2004). "Ksp-cadherin is a functional cell-cell adhesion molecule related to LI-cadherin". Exp. Cell Res. 294 (2): 345–55. doi:10.1016/j.yexcr.2003.11.022. PMID 15023525. 
  28. ^ Shibata T, Chuma M, Kokubu A, Sakamoto M, Hirohashi S (July 2003). "EBP50, a beta-catenin-associating protein, enhances Wnt signaling and is over-expressed in hepatocellular carcinoma". Hepatology 38 (1): 178–86. doi:10.1053/jhep.2003.50270. PMID 12830000. 
  29. ^ a b Oneyama C, Nakano H, Sharma SV (March 2002). "UCS15A, a novel small molecule, SH3 domain-mediated protein-protein interaction blocking drug". Oncogene 21 (13): 2037–50. doi:10.1038/sj.onc.1205271. PMID 11960376. 
  30. ^ a b Navarro P, Lozano E, Cano A (August 1993). "Expression of E- or P-cadherin is not sufficient to modify the morphology and the tumorigenic behavior of murine spindle carcinoma cells. Possible involvement of plakoglobin". J. Cell. Sci. 105 (4): 923–34. PMID 8227214. 
  31. ^ a b Takahashi K, Suzuki K, Tsukatani Y (July 1997). "Induction of tyrosine phosphorylation and association of beta-catenin with EGF receptor upon tryptic digestion of quiescent cells at confluence". Oncogene 15 (1): 71–8. doi:10.1038/sj.onc.1201160. PMID 9233779. 
  32. ^ Dobrosotskaya IY, James GL (April 2000). "MAGI-1 interacts with beta-catenin and is associated with cell-cell adhesion structures". Biochem. Biophys. Res. Commun. 270 (3): 903–9. doi:10.1006/bbrc.2000.2471. PMID 10772923. 
  33. ^ Geng L, Burrow CR, Li HP, Wilson PD (December 2000). "Modification of the composition of polycystin-1 multiprotein complexes by calcium and tyrosine phosphorylation". Biochim. Biophys. Acta 1535 (1): 21–35. doi:10.1016/S0925-4439(00)00079-X. PMID 11113628. 
  34. ^ Rao RK, Basuroy S, Rao VU, Karnaky Jr KJ, Gupta A (December 2002). "Tyrosine phosphorylation and dissociation of occludin-ZO-1 and E-cadherin-beta-catenin complexes from the cytoskeleton by oxidative stress". Biochem. J. 368 (Pt 2): 471–81. doi:10.1042/BJ20011804. PMC 1222996. PMID 12169098. 
  35. ^ Huber AH, Weis WI (May 2001). "The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin". Cell 105 (3): 391–402. doi:10.1016/S0092-8674(01)00330-0. PMID 11348595. 
  36. ^ a b Schmeiser K, Grand RJ (April 1999). "The fate of E- and P-cadherin during the early stages of apoptosis". Cell Death Differ. 6 (4): 377–86. doi:10.1038/sj.cdd.4400504. PMID 10381631. 
  37. ^ Pai R, Dunlap D, Qing J, Mohtashemi I, Hotzel K, French DM (July 2008). "Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling". Cancer Res. 68 (13): 5086–95. doi:10.1158/0008-5472.CAN-07-2325. PMID 18593907. 
  38. ^ Laoukili J, Alvarez-Fernandez M, Stahl M, Medema RH (September 2008). "FoxM1 is degraded at mitotic exit in a Cdh1-dependent manner". Cell Cycle 7 (17): 2720–6. doi:10.4161/cc.7.17.6580. PMID 18758239. 
  39. ^ a b Yoon YM, Baek KH, Jeong SJ, Shin HJ, Ha GH, Jeon AH, Hwang SG, Chun JS, Lee CW (September 2004). "WD repeat-containing mitotic checkpoint proteins act as transcriptional repressors during interphase". FEBS Lett. 575 (1-3): 23–9. doi:10.1016/j.febslet.2004.07.089. PMID 15388328. 
  40. ^ Li Z, Kim SH, Higgins JM, Brenner MB, Sacks DB (December 1999). "IQGAP1 and calmodulin modulate E-cadherin function". J. Biol. Chem. 274 (53): 37885–92. doi:10.1074/jbc.274.53.37885. PMID 10608854. 
  41. ^ Nourry C, Maksumova L, Pang M, Liu X, Wang T (May 2004). "Direct interaction between Smad3, APC10, CDH1 and HEF1 in proteasomal degradation of HEF1". BMC Cell Biol. 5: 20. doi:10.1186/1471-2121-5-20. PMC 420458. PMID 15144564. 
  42. ^ Shibata T, Gotoh M, Ochiai A, Hirohashi S (August 1994). "Association of plakoglobin with APC, a tumor suppressor gene product, and its regulation by tyrosine phosphorylation". Biochem. Biophys. Res. Commun. 203 (1): 519–22. doi:10.1006/bbrc.1994.2213. PMID 8074697. 
  43. ^ Hinck L, Näthke IS, Papkoff J, Nelson WJ (June 1994). "Dynamics of cadherin/catenin complex formation: novel protein interactions and pathways of complex assembly". J. Cell Biol. 125 (6): 1327–40. doi:10.1083/jcb.125.6.1327. PMC 2290923. PMID 8207061. 
  44. ^ Knudsen KA, Wheelock MJ (August 1992). "Plakoglobin, or an 83-kD homologue distinct from beta-catenin, interacts with E-cadherin and N-cadherin". J. Cell Biol. 118 (3): 671–9. doi:10.1083/jcb.118.3.671. PMC 2289540. PMID 1639850. 
  45. ^ Brady-Kalnay SM, Rimm DL, Tonks NK (1995). "Receptor protein tyrosine phosphatase PTPmu associates with cadherins and catenins in vivo.". J Cell Biol 130 (4): 977–86. doi:10.1083/jcb.130.4.977. PMC 2199947. PMID 7642713. 
  46. ^ Brady-Kalnay SM, Mourton T, Nixon JP, Pietz GE, Kinch M, Chen H et al. (1998). "Dynamic interaction of PTPmu with multiple cadherins in vivo.". J Cell Biol 141 (1): 287–96. doi:10.1083/jcb.141.1.287. PMC 2132733. PMID 9531566. 
  47. ^ Besco JA, Hooft van Huijsduijnen R, Frostholm A, Rotter A (2006). "Intracellular substrates of brain-enriched receptor protein tyrosine phosphatase rho (RPTPrho/PTPRT).". Brain Res 1116 (1): 50–7. doi:10.1016/j.brainres.2006.07.122. PMID 16973135. 
  48. ^ a b c Weinberg, Robert A. (April 2009). "Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits". Nat Rev Cancer 9 (4): 265–273. doi:10.1038/nrc2620. PMID 19262571. 
  49. ^ G Berx, et al. (December 1995). "E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis". EMBO J. 14 (24): 6107–6115. PMC 394735. 
  50. ^ G Berx, et al. (November 1996). "E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain.". Oncogene 13 (9): 1919–1925. PMID 8934538. 
  51. ^ Becker KF, et al. (November 1994). "E-cadherin gene mutations provide clues to diffuse type gastric carcinomas.". Cancer Res 54 (14): 3845–3852. PMID 8033105. 
  52. ^ De Leeuw WJ, et al. (December 1997). "Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ.". J Pathol. 183 (4): 404–411. doi:10.1002/(SICI)1096-9896(199712)183:4404::AID-PATH11483.0.CO;2-9. PMID 9496256. 
  53. ^ a b De Leeuw WJ, et al. (February 2000). "The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells.". Nat Cell Biol 2 (2): 84–89. doi:10.1038/35000034. PMID 10655587. 
  54. ^ a b Cano A, et al. (February 2000). "The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression.". Nat Cell Biol 2 (2): 76–83. doi:10.1038/35000025. PMID 10655586. 
  55. ^ a b Comijn J, et al. (June 2001). "The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion.". Mol Cell 7 (6): 1267–1278. doi:10.1016/S1097-2765(01)00260-X. PMID 11430829. 
  56. ^ a b Hajra KM, et al. (March 2002). "The SLUG zinc-finger protein represses E-cadherin in breast cancer.". Cancer Res 62 (6): 1613–1618. PMID 11912130. 
  57. ^ De Craene B, et al. (July 2005). "The transcription factor snail induces tumor cell invasion through modulation of the epithelial cell differentiation program.". Cancer Res. 65 (14): 6237–6244. doi:10.1158/0008-5472.CAN-04-3545. PMID 16024625. 
  58. ^ a b Yang J, et al. (June 2004). "Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis.". Cell 117 (7): 927–939. doi:10.1016/j.cell.2004.06.006. PMID 15210113. 
  59. ^ a b Eger A, et al. (Mar 2005). "DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells.". Oncogene 24 (14): 2375–85. doi:10.1038/sj.onc.1208429. PMID 15674322. 
  60. ^ Liu YN, et al. (Dec 2005). "Regulatory mechanisms controlling human E-cadherin gene expression.". Oncogene 24 (56): 8277–90. doi:10.1038/sj.onc.1208991. PMID 16116478. 
  61. ^ a b Lombaerts M, et al. (Mar 2006). "E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines.". Br J Cancer 94 (5): 661–71. doi:10.1038/sj.bjc.6602996. PMID 16495925. 
  62. ^ Graff JR, et al. (Jan 2000). "Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression.". J Biol Chem 275 (4): 2727–32. doi:10.1074/jbc.275.4.2727. PMID 10644736. 

Further reading[edit]

  • Berx G, Becker KF, Höfler H, van Roy F (1998). "Mutations of the human E-cadherin (CDH1) gene.". Hum. Mutat. 12 (4): 226–37. doi:10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D. PMID 9744472. 
  • Wijnhoven BP, Dinjens WN, Pignatelli M (2000). "E-cadherin-catenin cell-cell adhesion complex and human cancer.". The British journal of surgery 87 (8): 992–1005. doi:10.1046/j.1365-2168.2000.01513.x. PMID 10931041. 
  • Beavon IR (2000). "The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation.". Eur. J. Cancer 36 (13 Spec No): 1607–20. doi:10.1016/S0959-8049(00)00158-1. PMID 10959047. 
  • Wilson PD (2001). "Polycystin: new aspects of structure, function, and regulation.". J. Am. Soc. Nephrol. 12 (4): 834–45. PMID 11274246. 
  • Chun YS, Lindor NM, Smyrk TC, et al. (2001). "Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated?". Cancer 92 (1): 181–7. doi:10.1002/1097-0142(20010701)92:1<181::AID-CNCR1307>3.0.CO;2-J. PMID 11443625. 
  • Hazan RB, Qiao R, Keren R, et al. (2004). "Cadherin switch in tumor progression.". Ann. N. Y. Acad. Sci. 1014: 155–63. doi:10.1196/annals.1294.016. PMID 15153430. 
  • Bryant DM, Stow JL (2005). "The ins and outs of E-cadherin trafficking.". Trends Cell Biol. 14 (8): 427–34. doi:10.1016/j.tcb.2004.07.007. PMID 15308209. 
  • Wang HD, Ren J, Zhang L (2004). "CDH1 germline mutation in hereditary gastric carcinoma.". World J. Gastroenterol. 10 (21): 3088–93. PMID 15457549. 
  • Reynolds AB, Carnahan RH (2005). "Regulation of cadherin stability and turnover by p120ctn: implications in disease and cancer.". Semin. Cell Dev. Biol. 15 (6): 657–63. doi:10.1016/j.semcdb.2004.09.003. PMID 15561585. 
  • Moran CJ, Joyce M, McAnena OJ (2005). "CDH1 associated gastric cancer: a report of a family and review of the literature.". Eur J Surg Oncol 31 (3): 259–64. doi:10.1016/j.ejso.2004.12.010. PMID 15780560. 
  • Georgolios A, Batistatou A, Manolopoulos L, Charalabopoulos K (2006). "Role and expression patterns of E-cadherin in head and neck squamous cell carcinoma (HNSCC).". J. Exp. Clin. Cancer Res. 25 (1): 5–14. PMID 16761612. 
  • Renaud-Young M, Gallin WJ (2002). "In the first extracellular domain of E-cadherin, heterophilic interactions, but not the conserved His-Ala-Val motif, are required for adhesion". Journal of Biological Chemistry 277 (42): 39609–39616. doi:10.1074/jbc.M201256200. PMID 12154084. 

External links[edit]

This article incorporates text from the United States National Library of Medicine, which is in the public domain.